866-997-4948(US-Canada Toll Free)

Malignant Glioma - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : May 2013

Category :

Oncology

No. of Pages : 107 Pages


Global Markets Directs, \'Malignant Glioma Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Glioma. 

Malignant Glioma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Malignant Glioma.
  • A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Malignant Glioma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Malignant Glioma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Malignant Glioma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Malignant Glioma Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Malignant Glioma 8
Malignant Glioma Therapeutics under Development by Companies 10
Malignant Glioma Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Malignant Glioma Therapeutics - Products under Development by Companies 17
Malignant Glioma Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in Malignant Glioma Therapeutics Development 20
Boehringer Ingelheim GmbH 20
F. Hoffmann-La Roche Ltd. 21
Amgen Inc. 22
Sanofi-Aventis 23
AstraZeneca PLC 24
Eli Lilly and Company 25
Eisai Co., Ltd. 26
Oncolytics Biotech Inc. 27
Cytomedix, Inc. 28
Nerviano Medical Sciences S.r.l. 29
BioNumerik Pharmaceuticals, Inc. 30
Biovista Inc. 31
EirGen Pharma Ltd. 32
Malignant Glioma - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
lenvatinib - Drug Profile 39
rilotumumab - Drug Profile 42
SAR-245409 - Drug Profile 44
pelareorep - Drug Profile 46
imatinib + [everolimus] + [hydroxyurea] - Drug Profile 50
milciclib - Drug Profile 52
afatinib - Drug Profile 54
XL-765 + [temozolomide] - Drug Profile 56
cositecan - Drug Profile 57
cositecan - Drug Profile 59
afatinib + [temozolomide] - Drug Profile 61
bortezomib + [bevacizumab] - Drug Profile 63
Dendritic Vaccine Pulsed With Multiple Peptides - Drug Profile 64
celecoxib + Dendritic Cell Vaccine + [temozolomide] + Radiation Therapy - Drug Profile 65
Dendritic Cells + [imiquimod] - Drug Profile 67
bevacizumab - Drug Profile 68
Pan-HLA Peptide Vaccine - Drug Profile 72
galunisertib - Drug Profile 73
Survivin Peptide Vaccine + [Montanide ISA-51] + [sargramostim] - Drug Profile 75
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen - Drug Profile 76
Dendritic Cell + Dendritic Cell Activated Cytokine Induced Killer Cell - Drug Profile 77
Autologous Dendritic Cell Tumor Vaccine - Drug Profile 78
AZD-7451 - Drug Profile 79
carmustine SR - Drug Profile 80
Eir-060 - Drug Profile 81
ALD-451 - Drug Profile 82
DNX-2401 - Drug Profile 83
BVA-501 - Drug Profile 85
BVA-701 - Drug Profile 86
Malignant Glioma Therapeutics - Drug Profile Updates 87
Malignant Glioma Therapeutics - Discontinued Products 99
Malignant Glioma Therapeutics - Dormant Products 100
Malignant Glioma - Product Development Milestones 102
Featured News & Press Releases 102

Appendix 104
Methodology 104
Coverage 104
Secondary Research 104
Primary Research 104
Expert Panel Validation 104
Contact Us 105
Disclaimer 105

List of Table


Number of Products Under Development for Malignant Glioma, H1 2013 10
Products under Development for Malignant Glioma - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Investigation by Universities/Institutes, H1 2013 14
Comparative Analysis by Late Stage Development, H1 2013 15
Comparative Analysis by Mid Clinical Stage Development, H1 2013 16
Comparative Analysis by Early Clinical Stage Development, H1 2013 17
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 18
Products under Development by Companies, H1 2013 19
Products under Development by Companies, H1 2013 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2013 21
Boehringer Ingelheim GmbH, H1 2013 22
F. Hoffmann-La Roche Ltd., H1 2013 23
Amgen Inc., H1 2013 24
Sanofi-Aventis, H1 2013 25
AstraZeneca PLC, H1 2013 26
Eisai Co., Ltd., H1 2013 28
Oncolytics Biotech Inc., H1 2013 29
Cytomedix, Inc., H1 2013 30
Nerviano Medical Sciences S.r.l., H1 2013 31
BioNumerik Pharmaceuticals, Inc., H1 2013 32
Biovista Inc., H1 2013 33
EirGen Pharma Ltd., H1 2013 34
Assessment by Monotherapy Products, H1 2013 35
Assessment by Combination Products, H1 2013 36
Assessment by Stage and Route of Administration, H1 2013 38
Assessment by Stage and Molecule Type, H1 2013 40
Malignant Glioma Therapeutics - Drug Profile Updates 89
Malignant Glioma Therapeutics - Discontinued Products 101
Malignant Glioma Therapeutics - Dormant Products 102
Malignant Glioma Therapeutics - Dormant Products (Contd..1) 103

List of Chart


Number of Products under Development for Malignant Glioma, H1 2013 10
Products under Development for Malignant Glioma - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 14
Late Stage Products, H1 2013 15
Mid Clinical Stage Products, H1 2013 16
Early Clinical Stage Products, H1 2013 17
Pre-Clinical Stage Products, H1 2013 18
Assessment by Monotherapy Products, H1 2013 35
Assessment by Combination Products, H1 2013 36
Assessment by Route of Administration, H1 2013 37
Assessment by Stage and Route of Administration, H1 2013 38
Assessment by Molecule Type, H1 2013 39
Assessment by Stage and Molecule Type, H1 2013 40

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *